Apr.28.2025
Corporate

Revisions of Consolidated Financial Forecasts

Osaka, Japan, April 28, 2025 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino) today announced that it has revised its consolidated financial forecasts for the full-year period ending March 2025 disclosed at the announcement of Q2 financial results ending March 2025, made on October 31, 2024, as follows:

< IFRS (Full) basis >

  1. Revisions to the Full-Year Consolidated Financial Forecasts Ending March 2025
    (April 1, 2024 – March 31, 2025)
  2. (Millions of yen, except basic earnings per share)

     

    Revenue

    Operating profit

    Profit
    before tax

    Profit
    for the year

    Profit for the year attributable to owners of the Company

    Basic earnings per share (yen)

    Previous forecast (A)

    485,000

    82,000

    81,500

    58,100

    58,000

    123.49

    Revised forecast (B)

    487,000

    60,000

    60,000

    51,000

    50,000

    106.46

    Change (B-A)

    2,000

    (22,000)

    (21,500)

    (7,100)

    (8,000)

    -

    Change (%)

    0.4%

    (26.8%)

    (26.4%)

    (12.2%)

    (13.8%)

    -

    (Reference) Consolidated result of FY2023

    502,672

    159,935

    163,734

    128,040

    127,977

    266.61

  3. Reasons for the differences
    Revenue is forecasted to be ¥487.0 billion, an upward revision of ¥2.0 billion from the previously announced forecast. This increase is mainly due to royalty income from Bristol Myers Squibb for OPDIVO Intravenous Infusion is expected to exceed the previously announced forecast. Operating profit is forecasted to be ¥60.0 billion, a decrease of ¥22.0 billion from the previously announced forecast, mainly due to several factors: a sales milestone of ¥13.6 billion was recorded for FORXIGA Tablets, which were sold under a co-promotion agreement with AstraZeneca; amortization expenses were increased by approximately ¥7.0 billion compared to the previously announced forecast due to the revision of the amortization method for the increase in fair value of recognized inventory assets, related to the acquisition of Deciphera Pharmaceuticals, into the basis of actual inventory turnover; and the impairment loss of ¥2.5 billion on intangible assets was recorded for ONO-7018 (MALT1 inhibitor) due to the discontinuation of development.
    Profit for the year attributable to owners of the Company is forecasted to be ¥50.0 billion, a decrease of ¥8.0 billion from the previously announced forecast due to the expected decrease of tax expense by ¥14.0 billion mainly related to the increase in tax credit for research and development expenses, despite the expectation that the profit before tax is forecasted to be ¥60.0 billion, a decrease of ¥21.5 billion.

< Core basis >

  1. Revisions to the Full-Year Consolidated Financial Forecasts Ending March 2025
    (April 1, 2024 – March 31, 2025)
  2. (Millions of yen, except basic earnings per share)

     

    Revenue

    Core operating profit

    Core profit for the year

    Basic core earnings per share (yen)

    Previous forecast (A)

    485,000

    110,000

    81,000

    172.46

    Revised forecast (B)

    487,000

    113,000

    90,000

    191.63

    Change (B-A)

    2,000

    3,000

    9,000

    -

    Change (%)

    0.4%

    2.7%

    11.1%

    -

    (Reference) Consolidated result of FY2023

    502,672

    180,925

    142,545

    296.96

  3. Reasons for the differences
    Revenue is the same as on a IFRS (full) basis. Core operating profit is forecasted to be ¥113.0 billion, an upward revision of ¥3.0 billion from the previously announced forecast mainly due to an increase in gross profit. The following factors mentioned in operating profit of IFRS (Full) basis are deducted: the sales milestone of ¥13.6 billion for FORXIGA Tablets, the financial effect due to the revision of the amortization method for the increase in fair value of recognized inventory assets related to the acquisition of Deciphera Pharmaceuticals, and the impairment loss of ¥2.5 billion on intangible assets for ONO-7018 (MALT1 inhibitor). Core profit for the year is forecasted to be ¥90.0 billion, an upward revision of ¥9.0 billion from the previously announced forecast due to an expected decrease of tax expense by ¥6.0 billion mainly related to the increase in tax credit for research and development expenses.

    Note: The financial forecasts and statements contained in this announcement are prepared based on information that is available as of the date the announcement is made. Actual results may differ from those set forth in the announcements due to various uncertain factors.

    *Definition of core basis
    Core financial results are calculated by deducting items that are not inherently related to the Company's business performance or are one-time occurrences from the IFRS-based financial results. Adjustment items include amortization expenses arising from intangible assets acquired through acquisitions or in-licensing, impairment losses, compensation or settlement costs from litigation, and losses due to disasters.